Quick Summary
- What happened: The European Commission approved Amgen’s UPLIZNA® (inebilizumab) on February 12, 2026, as an add-on treatment for adults with generalized myasthenia gravis (gMG).
- First of its kind: UPLIZNA is now the first and only CD19-targeted therapy approved in Europe for gMG, covering both anti-AChR antibody-positive and anti-MuSK antibody-positive patients.
- Dosing advantage: After two initial loading infusions, patients require just one maintenance dose every six months, making it one of the most convenient dosing schedules in its class.
Amgen has secured European Commission approval for UPLIZNA® (inebilizumab) as a treatment for generalized myasthenia gravis (gMG), making it the first and only CD19-targeted therapy authorised in Europe for adults with either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive forms of the condition. The decision, announced February 12, 2026, opens a new chapter in the management of a disease that has long frustrated patients and physicians alike with its unpredictability and debilitating grip on everyday life.
The approval positions UPLIZNA as an add-on to standard therapy and introduces a notably patient-friendly dosing schedule: after two initial loading infusions, patients need only one maintenance dose every six months. For a population that often endures repeated hospital visits and complex multi-drug regimens, the twice-yearly maintenance represents a meaningful shift in how the disease can be managed over the long term.
This approval represents an important advancement for adults with gMG in Europe, helping address debilitating symptoms and potentially reduce the long-term use of steroids where clinically appropriate.
Cesar Sanz Rodrigue
A Disease That Quietly Dismantles Daily Life
Generalized myasthenia gravis is a rare, chronic autoimmune disorder in which the body’s immune system produces antibodies that attack the neuromuscular junction the critical interface where nerve signals instruct muscles to contract. The result is a fluctuating, often unpredictable pattern of muscle weakness that can affect breathing, swallowing, speech, and limb function. In severe cases, patients face myasthenic crises requiring intensive care.
Although it might appear to be an obscure condition, myasthenia gravis affects an estimated 56,000 to 123,000 people across Europe, and its prevalence is rising globally. The generalized form accounts for roughly 85 percent of all MG cases. Among those diagnosed, approximately 85 percent carry detectable antibodies against AChR, while roughly 7 percent have antibodies targeting MuSK a subgroup that has historically proven harder to treat.
The vast majority of generalized myasthenia gravis patients carry anti-AChR antibodies, which interfere with the neuromuscular junction. A smaller but clinically significant cohort, about 7%, carry anti-MuSK antibodies and have historically had fewer targeted treatment options.
Central to the disease’s pathology are CD19-positive B cells, including plasmablasts and plasma cells, which produce the damaging autoantibodies that impair neuromuscular communication. UPLIZNA was designed to intervene at precisely this point: the drug is a humanised monoclonal antibody that causes targeted and sustained depletion of these CD19+ cells, striking at the upstream source of the autoimmune cascade rather than merely managing downstream inflammation.
Read More: U.S. FDA Approves Amgen’s UPLIZNA® for Generalized Myasthenia Gravis in Adults
The Clinical Evidence: Largest Phase 3 Biologic Study of Its Kind
The EC approval rests on data from the Myasthenia Gravis Inebilizumab Trial known as MINT a randomised, double-blind, placebo-controlled study that enrolled 238 adults across international sites. MINT is notable for two reasons: it is the largest Phase 3 biologic trial to include both AChR-positive and MuSK-positive patients, and it was the first gMG study to successfully incorporate a structured steroid-tapering protocol from the outset.
The trial enrolled patients with MGFA classification II, III, or IV disease representing moderate to severe functional impairment — who were also on stable doses of steroids or nonsteroidal immunosuppressive therapy. The primary endpoint measured change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 26, a patient-reported tool assessing the impact of weakness on eight common functions including chewing, swallowing, breathing, and limb use.
| MG-ADL change, UPLIZNA (combined population) | −4.2 points |
| MG-ADL change, Placebo (combined population) | −2.2 points |
| Difference (primary endpoint, p<0.0001) | −1.9 points |
| QMG score change, UPLIZNA (combined population) | −4.8 points |
| QMG score change, Placebo (combined population) | −2.3 points |
| QMG difference (p=0.0002) | −2.5 points |
| Patients reducing steroids to ≤5 mg/day by Wk 26 (UPLIZNA) | 87.4% |
| Patients reducing steroids to ≤5 mg/day by Wk 26 (Placebo) | 84.6% |
Read More: U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder
Across both the primary endpoint and key secondary measures, UPLIZNA demonstrated statistically significant benefits over placebo. In the AChR-positive cohort, MG-ADL improvements continued to deepen through Week 52, with exploratory data showing a 2.8-point further separation from placebo. QMG scores a physician-assessed measure of objective muscle weakness across 13 domains showed a 4.3-point difference at one year for AChR-positive patients, suggesting that the drug’s effect on the underlying autoimmune process may intensify over time as CD19+ B cells remain depleted.
Results in the MuSK-positive cohort, while smaller in number (48 patients), showed a 2.2-point MG-ADL advantage that reached statistical significance. The QMG difference in this group did not reach the pre-specified significance threshold, but the directional benefit was consistent with the broader trial findings.
PLIZNA offers a new approach to treating gMG by selectively targeting CD19-positive B cells, which play a key role in disease pathology. The approval provides both clinicians and patients a valuable new treatment option with the potential for long-term efficacy while addressing the challenges of long-term steroid exposure.
John Vissing
The Steroid Question: A Quiet Revolution in Protocol Design
Perhaps as significant as the efficacy data is what MINT achieved in trial design. The study was the first in gMG to incorporate a structured, protocol-driven steroid taper from the start of the trial patients on corticosteroids at baseline began tapering at Week 4, with the goal of reaching prednisone 5 mg per day or less by Week 24. The fact that 87.4 percent of UPLIZNA patients achieved this threshold by Week 26 demonstrates that aggressive steroid reduction is feasible when patients are on effective disease-modifying therapy.
Long-term corticosteroid use remains one of the most significant sources of morbidity in gMG management. Weight gain, bone loss, diabetes, cardiovascular risk, and psychological effects from chronic steroid exposure are well-documented and substantially diminish quality of life in a patient population already burdened by the disease itself. The steroid-sparing potential of UPLIZNA, if confirmed in real-world practice, may prove to be as meaningful as the direct effects on muscle weakness.
A Third Approved Indication: Amgen’s Expanding Autoimmune Portfolio
The gMG approval represents UPLIZNA’s third authorised indication from the European Commission, reinforcing the drug’s credentials as a platform therapy for B-cell-mediated autoimmune disease. In November 2025, the EC approved UPLIZNA as the first and only treatment for active immunoglobulin G4-related disease (IgG4-RD), a rare chronic inflammatory condition that can affect multiple organs including the pancreas, kidneys, and major blood vessels. UPLIZNA had previously been approved in Europe as a monotherapy for anti-aquaporin-4 IgG seropositive neuromyelitis optica spectrum disorder (NMOSD), a devastating inflammatory disease of the central nervous system.
Globally, UPLIZNA has received regulatory endorsement from the U.S. Food and Drug Administration, Health Canada, and Brazil’s ANVISA across various indications, establishing an international regulatory track record that few rare disease drugs achieve in such a short time frame. The common immunological thread running through all three European indications, B-cell-driven autoimmunity, speaks to the coherence of Amgen’s therapeutic strategy with the drug.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
What Comes Next
The MINT trial includes an optional three-year open-label extension period, which will continue generating long-term safety and durability data. This extended follow-up will be closely watched by clinicians seeking to understand how stable CD19+ B cell depletion is maintained across years of twice-yearly dosing, and whether the emerging Week 52 efficacy signals in the AChR-positive population continue to strengthen over time.
For Amgen, the commercial opportunity in gMG adds to an already expanding rare disease franchise. The company will now need to navigate country-by-country reimbursement negotiations across Europe a process that typically introduces delays of 12 to 24 months between EC approval and broad patient access in key markets. Patient advocacy groups in neurology have long pressed for faster access pathways for diseases as severe as gMG, and the UPLIZNA data will likely be central to those conversations.
For patients across Europe who face a disease that can make swallowing a meal or climbing a flight of stairs an exhausting ordeal, and for the neurologists who have watched their treatment options remain relatively static for years, the approval of a first-in-class, twice-yearly CD19-targeted therapy is a genuinely significant development. The clinical question now shifts from whether the drug works to how best to integrate it into treatment algorithms, identify the patients most likely to respond deeply, and navigate the transition away from long-term steroid dependence.
Last Modified:
